212 related articles for article (PubMed ID: 36325893)
1. Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials.
González-Gil C; Morgades M; Lopes T; Fuster-Tormo F; García-Chica J; Zhao R; Montesinos P; Torrent A; Diaz-Beya M; Coll R; Hermosín L; Mercadal S; González-Campos J; Zamora L; Artola T; Vall-Llovera F; Tormo M; Gil-Cortés C; Barba P; Novo A; Ribera J; Bernal T; De Ugarriza PL; Queipo MP; Martínez-Sánchez P; Giménez A; González-Martínez T; Cladera A; Cervera J; Fernández-Martín R; Ardaiz MÁ; Vidal MJ; Baena Á; López-Bigas N; Bigas A; Maciejewski J; Orfao A; Ribera JM; Genescà E
Haematologica; 2023 Apr; 108(4):969-980. PubMed ID: 36325893
[TBL] [Abstract][Full Text] [Related]
2. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
[TBL] [Abstract][Full Text] [Related]
3. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
[No Abstract] [Full Text] [Related]
4. Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia.
Wang ZD; Wang YW; Xu LP; Zhang XH; Wang Y; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Wang YZ; Liu YR; Liu KY; Huang XJ; Chang YJ
Curr Med Sci; 2021 Jun; 41(3):443-453. PubMed ID: 34185250
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of
Yuan Y; Li J; Xue TL; Hu HR; Lin W; Liu SG; Zhang RD; Zheng HY; Gao C
Leuk Lymphoma; 2022 Jul; 63(7):1624-1633. PubMed ID: 35129045
[No Abstract] [Full Text] [Related]
6. [The Best Time of Minimal Residual Disease Monitoring for Predicting Survival and Prognosis in Children with T-Cell Acute Lymphoblastic Leukemia].
Bao H; Li TY; Wu YT; Xiao ZT; Zhang L; Luo LY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1471-1477. PubMed ID: 34627426
[TBL] [Abstract][Full Text] [Related]
7. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.
Petit A; Trinquand A; Chevret S; Ballerini P; Cayuela JM; Grardel N; Touzart A; Brethon B; Lapillonne H; Schmitt C; Thouvenin S; Michel G; Preudhomme C; Soulier J; Landman-Parker J; Leverger G; Macintyre E; Baruchel A; Asnafi V;
Blood; 2018 Jan; 131(3):289-300. PubMed ID: 29051182
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
Yu CH; Jou ST; Su YH; Coustan-Smith E; Wu G; Cheng CN; Lu MY; Lin KH; Wu KH; Chen SH; Huang FL; Chang HH; Wang JL; Yen HJ; Li MJ; Chou SW; Ho WL; Liu YL; Chang CC; Lin ZS; Lin CY; Chen HY; Ni YL; Lin DT; Lin SW; Yang JJ; Ni YH; Pui CH; Yu SL; Yang YL
Cancer; 2023 Mar; 129(5):790-802. PubMed ID: 36537587
[TBL] [Abstract][Full Text] [Related]
9. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
10. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Eckert C; Hrusak O; Buldini B; Sartor M; Zugmaier G; Zeng Y; Pilankar D; Morris J; von Stackelberg A
Pediatr Blood Cancer; 2022 Aug; 69(8):e29715. PubMed ID: 35482538
[TBL] [Abstract][Full Text] [Related]
11. Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia.
Combariza JF; Arango M; Díaz L; Agudelo C; Hernandez S; Madera AM; León G; Avila V; Bautista L; Valdés J; Orduz R; Mejía F; Moreno L; Ramirez C
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e365-e372. PubMed ID: 33277225
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.
Ribera J; Zamora L; Morgades M; Vives S; Granada I; Montesinos P; Gómez-Seguí I; Mercadal S; Guàrdia R; Nomdedeu J; Pratcorona M; Tormo M; Martínez-Lopez J; Hernández-Rivas JM; Ciudad J; Orfao A; González-Campos J; Barba P; Escoda L; Esteve J; Genescà E; Solé F; Feliu E; Ribera JM; ;
Genes Chromosomes Cancer; 2019 Nov; 58(11):815-819. PubMed ID: 31340073
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
14. The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients.
Ribera J; Granada I; Morgades M; Vives S; Genescà E; González C; Nomdedeu J; Escoda L; Montesinos P; Mercadal S; Coll R; González-Campos J; Abella E; Barba P; Bermúdez A; Gil C; Tormo M; Pedreño M; Martínez-Carballeira D; Hernández-Rivas JM; Orfao A; Martínez-López J; Esteve J; Bravo P; Garcia-Guiñon A; Debén G; Moraleda JM; Queizán JA; Ortín X; Moreno MJ; Feliu E; Solé F; Ribera JM;
Br J Haematol; 2019 Jul; 186(2):263-268. PubMed ID: 30916384
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
[TBL] [Abstract][Full Text] [Related]
16. Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials.
Ribera JM; Morgades M; Genescà E; Chapchap EC; Montesinos P; Acuña-Cruz E; Gil C; García-Cadenas I; Barba P; González-Campos J; Queipo de Llano MP; Torrent A; Ribera J; Granada I; Bernal T; Díaz-Beyá M; Amigo ML; Coll R; Tormo M; Vall-Llovera F; Gómez-Centurión I; Sánchez-Sánchez MJ; Soria B; Cladera A; Artola MT; Garcia-Guiñon A; Giménez-Conca A; Amador ML; Martínez-Sánchez P; Algarra JL; Vidal MJ; Alonso N; Maluquer C; Llorente L; García-Boyero R; Ciudad J; Feliu E; Orfao A;
Hematol Oncol; 2021 Oct; 39(4):529-538. PubMed ID: 34405901
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
19. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
20. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
